(Q46560906)

23 December 2017

title

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy (English)

1 reference

23 December 2017

chronic phase chronic myelogenous leukemia

main subject

0 references

1 reference

1 reference

1

Hagop M Kantarjian

1 reference

23 December 2017

6

Stefan Faderl

1 reference

23 December 2017

7

William Wierda

1 reference

23 December 2017

4

Susan O'Brien

1 reference

23 December 2017

8

Mary Beth Rios

1 reference

23 December 2017

5

Francis Giles

1 reference

23 December 2017

10

Jorge Cortes

1 reference

23 December 2017

2

Carlos E Bueso-Ramos

1 reference

23 December 2017

Jianqin Shan

series ordinal

9

object named as

Jianqin Shan

1 reference

23 December 2017

Moshe Talpaz

series ordinal

3

object named as

Moshe Talpaz

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

23 December 2017

published in

Cancer

1 reference

23 December 2017

volume

104

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

777-780

1 reference

23 December 2017

Chronic myelogenous leukemia: a review and update of therapeutic strategies

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21235

7 January 2021

Identifiers

DOI

10.1002/CNCR.21235

1 reference

23 December 2017

PubMed ID

15971197

1 reference

23 December 2017